144 related articles for article (PubMed ID: 18774870)
1. The lifetime cost of hepatocellular carcinoma : a claims data analysis from a medical centre in Taiwan.
Lang HC; Wu JC; Yen SH; Lan CF; Wu SL
Appl Health Econ Health Policy; 2008; 6(1):55-65. PubMed ID: 18774870
[TBL] [Abstract][Full Text] [Related]
2. Health care costs associated with hepatocellular carcinoma: a population-based study.
Thein HH; Isaranuwatchai W; Campitelli MA; Feld JJ; Yoshida E; Sherman M; Hoch JS; Peacock S; Krahn MD; Earle CC
Hepatology; 2013 Oct; 58(4):1375-84. PubMed ID: 23300063
[TBL] [Abstract][Full Text] [Related]
3. Lifetime costs of the top five cancers in Taiwan.
Lang HC; Wu SL
Eur J Health Econ; 2012 Jun; 13(3):347-53. PubMed ID: 21442437
[TBL] [Abstract][Full Text] [Related]
4. Consumption of national health insurance medical resources by hepatocellular carcinoma patients treated using radiofrequency ablation therapy.
Kung CM; Mo LR; Yan YH
Asia Pac J Clin Oncol; 2012 Sep; 8(3):275-81. PubMed ID: 22897713
[TBL] [Abstract][Full Text] [Related]
5. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan.
Nguang SH; Wu CK; Liang CM; Tai WC; Yang SC; Ku MK; Yuan LT; Wang JW; Tseng KL; Hung TH; Hsu PI; Wu DC; Chuah SK; Hsu CN
Int J Environ Res Public Health; 2018 Nov; 15(12):. PubMed ID: 30486324
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan.
Shih ST; Crowley S; Sheu JC
J Formos Med Assoc; 2010 Jan; 109(1):39-55. PubMed ID: 20123585
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.
Kuo MJ; Chen HH; Chen CL; Fann JC; Chen SL; Chiu SY; Lin YM; Liao CS; Chang HC; Lin YS; Yen AM
World J Gastroenterol; 2016 Mar; 22(12):3460-70. PubMed ID: 27022228
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.
Kaplan DE; Chapko MK; Mehta R; Dai F; Skanderson M; Aytaman A; Baytarian M; D'Addeo K; Fox R; Hunt K; Pocha C; Valderrama A; Taddei TH;
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):106-114.e5. PubMed ID: 28756056
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Ho JC; Hsieh ML; Chuang PH; Hsieh VC
Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
[TBL] [Abstract][Full Text] [Related]
10. Hospice offers more palliative care but costs less than usual care for terminal geriatric hepatocellular carcinoma patients: a nationwide study.
Hwang SJ; Chang HT; Hwang IH; Wu CY; Yang WH; Li CP
J Palliat Med; 2013 Jul; 16(7):780-5. PubMed ID: 23790184
[TBL] [Abstract][Full Text] [Related]
11. A retrospective matched case-control study on medical costs of refractory migraine in Taiwan.
Tang CH; Chen YC; Ng K; Wang SJ
Headache; 2013 Mar; 53(3):526-39. PubMed ID: 23406446
[TBL] [Abstract][Full Text] [Related]
12. Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005).
Marinho RT; Giria J; Moura MC
World J Gastroenterol; 2007 Mar; 13(10):1522-7. PubMed ID: 17461443
[TBL] [Abstract][Full Text] [Related]
13. Cost of chronic hepatitis B virus infection in Taiwan.
Hsieh CR; Kuo CW
J Clin Gastroenterol; 2004; 38(10 Suppl 3):S148-52. PubMed ID: 15602163
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the financial burden to the National Health Insurance for patients with major cancers in Taiwan.
Chu PC; Hwang JS; Wang JD; Chang YY
J Formos Med Assoc; 2008 Jan; 107(1):54-63. PubMed ID: 18218578
[TBL] [Abstract][Full Text] [Related]
15. The burden of illness associated with hepatocellular carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Shah S; Thompson D
J Hepatol; 2009 Jan; 50(1):89-99. PubMed ID: 18977551
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
17. Mortality and hospital utilization for hepatocellular carcinoma in the United States.
Kim WR; Gores GJ; Benson JT; Therneau TM; Melton LJ
Gastroenterology; 2005 Aug; 129(2):486-93. PubMed ID: 16083705
[TBL] [Abstract][Full Text] [Related]
18. Phase-specific and lifetime costs of cancer care in Ontario, Canada.
de Oliveira C; Pataky R; Bremner KE; Rangrej J; Chan KK; Cheung WY; Hoch JS; Peacock S; Krahn MD
BMC Cancer; 2016 Oct; 16(1):809. PubMed ID: 27756310
[TBL] [Abstract][Full Text] [Related]
19. Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan.
Liao YH; Lin CC; Li TC; Lin JG
BMC Complement Altern Med; 2012 Sep; 12():146. PubMed ID: 22947144
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.
Qian MY; Yuwei J R; Angus P; Schelleman T; Johnson L; Gow P
J Gastroenterol Hepatol; 2010 May; 25(5):951-6. PubMed ID: 20546449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
